Canada markets open in 6 hours 33 minutes

Defence Therapeutics Inc. (DTC.CN)

Canadian Sec - Canadian Sec Real Time Price. Currency in CAD
Add to watchlist
1.1400-0.0100 (-0.87%)
At close: 03:59PM EDT
Full screen
Previous Close1.1500
Open0.0000
Bid0.0000 x N/A
Ask0.0000 x N/A
Day's Range0.0000 - 0.0000
52 Week Range
Volume0
Avg. Volume32,909
Market Cap51.798M
Beta (5Y Monthly)1.51
PE Ratio (TTM)N/A
EPS (TTM)-0.1900
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Newsfile

    Defence Therapeutics Strengthens and Expands Global Patent Protection on Key Technologies

    Vancouver, British Columbia--(Newsfile Corp. - May 14, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a Canadian biopharmaceutical company developing novel immune-oncology vaccines and drug delivery technologies, is pleased to announce the issuance of several new patents, as well as new allowances of patent applications belonging to different Patent Families in Defence's vast and diverse portfolio.Defence's vaccine enhancer platform technolog

  • Newsfile

    Pancreatic Cancer: Successful Trial Against Pancreatic Cancer with Defence Therapeutics' ARM-002 Anti-Cancer Vaccine

    Vancouver, British Columbia--(Newsfile Corp. - May 1, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC), ("Defence" or the "Company"), a Canadian biopharmaceutical company developing novel immune-oncology therapeutics and drug delivery technologies, is pleased to announce the successful completion of a pre-clinical vaccination trial using its ARM-002TM vaccine against pancreatic cancer. The vaccine was shown to be therapeutically effective against pre-established pancreatic

  • Newsfile

    Defence's AccuTOX Anti-Cancer ARM-002 Vaccine Exhibits Potent Antigen Presentation

    Vancouver, British Columbia--(Newsfile Corp. - April 23, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a Canadian biopharmaceutical company developing novel immune-oncology therapeutics and drug delivery technologies, is pleased to announce that its second-generation ARMTM anti-cancer vaccine using AccuTOX®, called ARM-002TM, is therapeutically effective against pre-established melanoma when combined with the anti-PD-1 immune-checkpoint inhi